A look at Novavax, Inc’s (NVAX) recent performance gives investors their first glimpse of hope.

On Tuesday, Novavax, Inc (NASDAQ: NVAX) opened lower -3.18% from the last session, before settling in for the closing price of $8.18. Price fluctuations for NVAX have ranged from $3.81 to $23.86 over the past 52 weeks.

Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 516.28%. Company’s average yearly earnings per share was noted 80.37% at the time writing. With a float of $146.60 million, this company’s outstanding shares have now reached $160.42 million.

Considering the fact that the conglomerate employs 952 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 73.3%, operating margin of -35.6%, and the pretax margin is -25.89%.

Novavax, Inc (NVAX) Insider Activity

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Novavax, Inc is 8.86%, while institutional ownership is 59.80%. The most recent insider transaction that took place on Dec 13 ’24, was worth 37,435. In this transaction Director of this company sold 4,150 shares at a rate of $9.02, taking the stock ownership to the 14,770 shares. Before that another transaction happened on Dec 31 ’24, when Company’s Director sold 5,400 for $8.00, making the entire transaction worth $43,200. This insider now owns 51,760 shares in total.

Novavax, Inc (NVAX) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.2 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 80.37% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 51.01% during the next five years compared to 25.88% growth over the previous five years of trading.

Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators

Check out the current performance indicators for Novavax, Inc (NVAX). In the past quarter, the stock posted a quick ratio of 0.97. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.87.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach 0.53 in one year’s time.

Technical Analysis of Novavax, Inc (NVAX)

Compared to the last year’s volume of 4.6 million, its volume of 3.8 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 69.98%. Additionally, its Average True Range was 0.60.

During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 18.35%, which indicates a significant decrease from 55.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.43% in the past 14 days, which was higher than the 75.69% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $8.43, while its 200-day Moving Average is $11.17. Nevertheless, the first resistance level for the watch stands at $8.28 in the near term. At $8.64, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.96. If the price goes on to break the first support level at $7.61, it is likely to go to the next support level at $7.29. Should the price break the second support level, the third support level stands at $6.93.

Novavax, Inc (NASDAQ: NVAX) Key Stats

There are currently 160,844K shares outstanding in the company with a market cap of 1.27 billion. Presently, the company’s annual sales total 682,160 K according to its annual income of -187,500 K. Last quarter, the company’s sales amounted to 88,310 K and its income totaled -81,030 K.